Aaa Drug Patent Portfolio
Aaa owns 1 orange book drug protected by 18 US patents Given below is the list of Aaa's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10596276 | Stable, concentrated radionuclide complex solutions | 25 Jan, 2039 | Active |
| US10596278 | Stable, concentrated radionuclide complex solutions | 25 Jan, 2039 | Active |
| US11904027 | Stable, concentrated radionuclide complex solutions | 25 Jan, 2039 | Active |
| US12144873 | Stable, concentrated radionuclide complex solutions | 25 Jan, 2039 | Active |
| US12151003 | Stable, concentrated radionuclide complex solutions | 25 Jan, 2039 | Active |
| US12161732 | Stable, concentrated radionuclide complex solutions | 25 Jan, 2039 | Active |
| US12168063 | Stable, Concentrated Radionuclide Complex Solutions | 25 Jan, 2039 | Active |
| US12415003 | Stable, Concentrated Radionuclide Complex Solutions | 25 Jan, 2039 | Active |
| US12491272 | Stable, Concentrated Radionuclide Complex Solutions | 25 Jan, 2039 | Active |
| US10596276 | Stable, concentrated radionuclide complex solutions | 25 Jul, 2038 | Active |
| US10596278 | Stable, concentrated radionuclide complex solutions | 25 Jul, 2038 | Active |
| US11904027 | Stable, concentrated radionuclide complex solutions | 25 Jul, 2038 | Active |
| US12144873 | Stable, concentrated radionuclide complex solutions | 25 Jul, 2038 | Active |
| US12151003 | Stable, concentrated radionuclide complex solutions | 25 Jul, 2038 | Active |
| US12161732 | Stable, concentrated radionuclide complex solutions | 25 Jul, 2038 | Active |
| US12168063 | Stable, concentrated radionuclide complex solutions | 25 Jul, 2038 | Active |
| US12415003 | Stable, Concentrated Radionuclide Complex Solutions | 25 Jul, 2038 | Active |
| US12491272 | Stable, Concentrated Radionuclide Complex Solutions | 25 Jul, 2038 | Active |
Latest Legal Activities on Aaa's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Aaa.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Recordation of Patent Grant Mailed | 16 Dec, 2025 | US12491272 |
| Patent Issue Date Used in PTA Calculation | 09 Dec, 2025 | US12491272 |
| Recordation of Patent eGrant | 09 Dec, 2025 | US12491272 |
| Patent eGrant Notification | 09 Dec, 2025 | US12491272 |
| Email Notification | 09 Dec, 2025 | US12491272 |
| Mail Patent eGrant Notification | 09 Dec, 2025 | US12491272 |
| Email Notification | 27 Nov, 2025 | US12491272 |
| Issue Notification Mailed | 26 Nov, 2025 | US12491272 |
| Dispatch to FDC | 13 Nov, 2025 | US12491272 |
| Application Is Considered Ready for Issue | 13 Nov, 2025 | US12491272 |
| Filing Receipt - Corrected | 12 Nov, 2025 | US12491272 |
| Email Notification | 12 Nov, 2025 | US12491272 |
| Miscellaneous Incoming Letter | 06 Oct, 2025 | US12491272 |
| Recordation of Patent Grant Mailed | 23 Sep, 2025 | US12415003 |
| Email Notification | 17 Sep, 2025 | US12415003 |
Aaa's Drug Patent Litigations
Aaa's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 02, 2020, against patent number US10596278. The petitioner Evergreen Theragnostics, Inc., challenged the validity of this patent, with Advanced Accelerator Applications SA as the respondent. Click below to track the latest information on how companies are challenging Aaa's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US10596276 | October, 2020 |
Institution Denied
(14 Apr, 2021)
| Advanced Accelerator Applications SA | Evergreen Theragnostics, Inc. |
| US10596278 | October, 2020 |
Institution Denied
(14 Apr, 2021)
| Advanced Accelerator Applications SA | Evergreen Theragnostics, Inc. |
Aaa's Family Patents
Aaa drugs have patent protection in a total of 16 countries. It's US patent count contributes only to 27.8% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click
below to unlock the full patent family tree.
Clinical Trials
Recent Clinical Trials by Aaa:
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Suvorexant for Alcohol Use Disorder (AUD): Neural Mechanisms | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | NA |
RECRUITING
(Aug 6, 2026)
| PHASE1, PHASE2 |
| Role of Metal Ion Transporter ZIP8 in Alcohol-Related Behaviors | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | NA |
RECRUITING
(Jul 30, 2026)
| PHASE1 |
| Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD) | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | NA |
RECRUITING
(Jul 22, 2026)
| PHASE1 |
| Tirzepatide in MetALD | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | NA |
RECRUITING
(Jul 16, 2026)
| PHASE2 |
| Nicotinic Receptor Genetic Variation and Alcohol Reward | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | NA |
RECRUITING
(Jun 25, 2026)
| PHASE1 |
| Human Laboratory Study of Apremilast for Alcohol Use Disorder | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | NA |
RECRUITING
(Apr 1, 2026)
| PHASE2 |
Aaa Drug List
Given below is the complete list of Aaa's drugs and the patents protecting them.
1. Lutathera
Lutathera is protected by 18 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10596276
(Pediatric)
| Stable, concentrated radionuclide complex solutions |
25 Jan, 2039
(12 years from now)
| Active |
| US10596278
(Pediatric)
| Stable, concentrated radionuclide complex solutions |
25 Jan, 2039
(12 years from now)
| Active |
| US11904027
(Pediatric)
| Stable, concentrated radionuclide complex solutions |
25 Jan, 2039
(12 years from now)
| Active |
| US12144873
(Pediatric)
| Stable, concentrated radionuclide complex solutions |
25 Jan, 2039
(12 years from now)
| Active |
| US12151003
(Pediatric)
| Stable, concentrated radionuclide complex solutions |
25 Jan, 2039
(12 years from now)
| Active |
| US12161732
(Pediatric)
| Stable, concentrated radionuclide complex solutions |
25 Jan, 2039
(12 years from now)
| Active |
| US12168063
(Pediatric)
| Stable, Concentrated Radionuclide Complex Solutions |
25 Jan, 2039
(12 years from now)
| Active |
| US12415003
(Pediatric)
| Stable, Concentrated Radionuclide Complex Solutions |
25 Jan, 2039
(12 years from now)
| Active |
| US12491272
(Pediatric)
| Stable, Concentrated Radionuclide Complex Solutions |
25 Jan, 2039
(12 years from now)
| Active |
| US10596276 | Stable, concentrated radionuclide complex solutions |
25 Jul, 2038
(11 years from now)
| Active |
| US10596278 | Stable, concentrated radionuclide complex solutions |
25 Jul, 2038
(11 years from now)
| Active |
| US11904027 | Stable, concentrated radionuclide complex solutions |
25 Jul, 2038
(11 years from now)
| Active |
| US12144873 | Stable, concentrated radionuclide complex solutions |
25 Jul, 2038
(11 years from now)
| Active |
| US12151003 | Stable, concentrated radionuclide complex solutions |
25 Jul, 2038
(11 years from now)
| Active |
| US12161732 | Stable, concentrated radionuclide complex solutions |
25 Jul, 2038
(11 years from now)
| Active |
| US12168063 | Stable, concentrated radionuclide complex solutions |
25 Jul, 2038
(11 years from now)
| Active |
| US12415003 | Stable, Concentrated Radionuclide Complex Solutions |
25 Jul, 2038
(11 years from now)
| Active |
| US12491272 | Stable, Concentrated Radionuclide Complex Solutions |
25 Jul, 2038
(11 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lutathera's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List